Streetbeat News

Revenues

HII

Huntington Ingalls Industries (NYSE:HII) reported Q2 2024 earnings per share (EPS) of $4.38, surpassing the analyst consensus estimate of $3.57 by 22.69%. The company also reported quarterly sales of $2.977 billion, exceeding the analyst consensus estimate of $2.845 billion by 4.65%. This represents a 6.82% increase over sales of $2.787 billion in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:16 am

LH

Labcorp has adjusted its FY24 outlook, cutting its adjusted EPS guidance from $14.45-$15.35 to $14.30-$14.90, which is below the $14.82 estimate. However, the company has raised its revenue growth outlook from 4.8%-6.4% to 6.4%-7.5%, surpassing the $12.83 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:16 am

APPN

Appian Corporation (APPN) has released its full-year 2024 guidance, expecting total revenue between $610M and $615M, slightly below the $615.69M estimate. The company anticipates an adjusted EPS loss between $(0.61) and $(0.52), better than the $(0.80) estimate. Cloud subscription revenue is projected to grow by 18% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:15 am

LEE

Lee Enterprises has reaffirmed its 2024 digital revenue guidance of $310M-$330M, representing a 13%-21% year-over-year increase. However, the company has updated its adjusted EBITDA guidance to $73M-$78M, down from the prior $83M-$90M. Digital-only subscribers are expected to grow by 7% year-over-year to 771,000.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:15 am

TAC

TransAlta (NYSE:TAC) reported Q2 earnings per share of $0.13, beating the analyst estimate of $0.07 by 85.71%. Sales were $425.41 million, surpassing the $331.77 million estimate by 28.23%. However, both EPS and sales were down compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:14 am

PASG

Passage Bio (NASDAQ:PASG) has out-licensed three pediatric lysosomal storage disease programs to GEMMA Biotherapeutics for $20M in initial payments and up to $114M in milestones, plus future royalties. GEMMABio will assume financial obligations and Passage Bio will support the transition.

Portfolio Pulse from charles@benzinga.com

August 01, 2024 | 11:13 am

APPN

Appian has provided its Q3 2024 guidance, expecting total revenue between $149M and $153M, surpassing the $142.95M estimate. The company also anticipates a non-GAAP net loss per share between $(0.10) and $(0.06), better than the $(0.31) estimate.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:13 am

OMCL

Omnicell (NASDAQ:OMCL) reported Q2 earnings of $0.51 per share, significantly beating the analyst estimate of $0.14. Sales were $276.79 million, also surpassing the $255.20 million estimate. Despite these beats, both earnings and sales were down compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:12 am

WLFC

Willis Lease Finance reported a significant increase in its Q2 2024 GAAP EPS, rising to $6.21 from $2.02 year-over-year. Sales also saw a substantial increase, reaching $151.12 million, up from $109.00 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:12 am

LEE

Lee Enterprises (NASDAQ:LEE) reported a significant decline in its Q3 earnings, with a loss of $(0.73) per share compared to a profit of $0.25 per share in the same period last year. Sales also decreased by 12.10% to $150.58 million from $171.31 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:12 am